GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Getein Biotech Inc (SHSE:603387) » Definitions » Cash Flow from Investing

Getein Biotech (SHSE:603387) Cash Flow from Investing : ¥-561 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Getein Biotech Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Getein Biotech spent ¥37 Mil on purchasing property, plant, equipment. It gained ¥0 Mil from selling property, plant, and equipment. It spent ¥0 Mil on purchasing business. It gained ¥0 Mil from selling business. It spent ¥145 Mil on purchasing investments. It gained ¥81 Mil from selling investments. It paid ¥0Mil for net Intangibles purchase and sale. And it received ¥0 Mil from other investing activities. In all, Getein Biotech spent ¥100 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Getein Biotech Cash Flow from Investing Historical Data

The historical data trend for Getein Biotech's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Getein Biotech Cash Flow from Investing Chart

Getein Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 261.76 -238.71 -254.63 -760.44 -356.83

Getein Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.60 -260.02 -192.68 -7.73 -100.42

Getein Biotech Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Getein Biotech's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Getein Biotech's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-561 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Getein Biotech  (SHSE:603387) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Getein Biotech's purchase of property, plant, equipment for the three months ended in Mar. 2024 was ¥-37 Mil. It means Getein Biotech spent ¥37 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Getein Biotech's sale of property, plant, equipment for the three months ended in Mar. 2024 was ¥0 Mil. It means Getein Biotech gained ¥0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Getein Biotech's purchase of business for the three months ended in Mar. 2024 was ¥0 Mil. It means Getein Biotech spent ¥0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Getein Biotech's sale of business for the three months ended in Mar. 2024 was ¥0 Mil. It means Getein Biotech gained ¥0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Getein Biotech's purchase of investment for the three months ended in Mar. 2024 was ¥-145 Mil. It means Getein Biotech spent {stock_data.stock.currency_symbol}}145 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Getein Biotech's sale of investment for the three months ended in Mar. 2024 was ¥81 Mil. It means Getein Biotech gained ¥81 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Getein Biotech's net Intangibles purchase and sale for the three months ended in Mar. 2024 was ¥0 Mil. It means Getein Biotech paid ¥0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Getein Biotech's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0 Mil. It means Getein Biotech paid ¥0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Getein Biotech's cash from other investing activities for the three months ended in Mar. 2024 was ¥0 Mil. It means Getein Biotech received ¥0 Mil from other investing activities.


Getein Biotech Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Getein Biotech's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Getein Biotech (SHSE:603387) Business Description

Traded in Other Exchanges
N/A
Address
No. 9 Bofu Road, Luhe District, Nanjing, CHN, 211505
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
Executives
Su En Kui Director
Yan Bin Director
Kong Ting Ting Director
Xu Xing De Director
Su En Ben Director

Getein Biotech (SHSE:603387) Headlines

No Headlines